Genmab A/S
GMAB
$22.07
-$0.13-0.59%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 715.00M | 920.51M | 816.36M | 779.45M | 603.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 715.00M | 920.51M | 816.36M | 779.45M | 603.00M |
| Cost of Revenue | 42.00M | 48.16M | 40.23M | 27.42M | 27.00M |
| Gross Profit | 673.00M | 872.35M | 776.13M | 752.04M | 576.00M |
| SG&A Expenses | 126.00M | 178.50M | 127.46M | 129.00M | 125.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 527.00M | 596.52M | 504.11M | 517.42M | 487.00M |
| Operating Income | 188.00M | 323.99M | 312.25M | 262.03M | 116.00M |
| Income Before Tax | 244.00M | 514.78M | 253.31M | 306.90M | 249.00M |
| Income Tax Expenses | 49.00M | -34.73M | 66.75M | 103.74M | 57.00M |
| Earnings from Continuing Operations | 195.00M | 549.50M | 186.55M | 203.16M | 192.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 195.00M | 549.50M | 186.55M | 203.16M | 192.00M |
| EBIT | 188.00M | 323.99M | 312.25M | 262.03M | 116.00M |
| EBITDA | 200.00M | 336.56M | 324.78M | 271.99M | 126.00M |
| EPS Basic | 0.44 | 8.65 | 2.94 | 3.15 | 0.43 |
| Normalized Basic EPS | 0.32 | 5.23 | 2.31 | 3.12 | 0.28 |
| EPS Diluted | 0.44 | 8.57 | 2.92 | 3.13 | 0.43 |
| Normalized Diluted EPS | 0.32 | 5.18 | 2.30 | 3.10 | 0.28 |
| Average Basic Shares Outstanding | 439.82M | 63.53M | 63.49M | 64.44M | 448.48M |
| Average Diluted Shares Outstanding | 441.26M | 64.15M | 63.91M | 64.88M | 451.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |